| Literature DB >> 25003118 |
Ewa Wardal1, Katarzyna Markowska1, Dorota Zabicka1, Marta Wróblewska2, Małgorzata Giemza2, Ewa Mik2, Hanna Połowniak-Pracka3, Agnieszka Woźniak3, Waleria Hryniewicz1, Ewa Sadowy1.
Abstract
Vancomycin-resistant Enterococcus faecium represents a growing threat in hospital-acquired infections. Two outbreaks of this pathogen from neighboring Warsaw hospitals have been analyzed in this study. Pulsed-field gel electrophoresis (PFGE) of SmaI-digested DNA, multilocus VNTR analysis (MLVA), and multilocus sequence typing (MLST) revealed a clonal variability of isolates which belonged to three main lineages (17, 18, and 78) of nosocomial E. faecium. All isolates were multidrug resistant and carried several resistance, virulence, and plasmid-specific genes. Almost all isolates shared the same variant of Tn1546 transposon, characterized by the presence of insertion sequence ISEf1 and a point mutation in the vanA gene. In the majority of cases, this transposon was located on 50 kb or 100 kb pRUM-related plasmids, which lacked, however, the axe-txe toxin-antitoxin genes. 100 kb plasmid was easily transferred by conjugation and was found in various clonal backgrounds in both institutions, while 50 kb plasmid was not transferable and occurred solely in MT159/ST78 strains that disseminated clonally in one institution. Although molecular data indicated the spread of VRE between two institutions or a potential common source of this alert pathogen, epidemiological investigations did not reveal the possible route by which outbreak strains disseminated.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25003118 PMCID: PMC4070583 DOI: 10.1155/2014/575367
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Primers used in the analysis of Tn1546 transposon.
| Primer pair | Primer names | Sequence (5′-3′) | Position in Tn | Application in this study | Reference |
|---|---|---|---|---|---|
| 1 | vanRSHAX-1 | AGACAAGTCTGAGATTGACCTTGCC | 4141–4165 | PCR | [ |
| vanRSHAX-2 | ATATGCTTCAAACCCACTGTTTTCC | 8565–8589 | PCR | [ | |
| 2 | Tn | GGAAAATGCGGATTTACAACGCTAAG | 13–38 | PCR | [ |
| ORF1-5 | CACGTCCTGCCGACTATGATTATTT | 1900–1876 | PCR | [ | |
| 3 | ORF2-F | TCATTCCATTTCTGTATTTTCAATTT | 3050–3086 | PCR | [ |
| ORF2-R | GCCCATTAGCGGAATACAGA | 3770–3751 | PCR | [ | |
| 4 | ORF2-F2 | ACTAATGTATCTAGGGCTTCA | 3710–3731 | PCR | [ |
| vanR-R | GCAATTTCATGTTCATCATCCA | 4000–3979 | PCR | [ | |
| 5 | vanS | AACGCTATTCCAAACTAGAA | 4690–4710 | PCR, sequencing | [ |
| vanS-R | GTCGGAAGCTCTACCCTAAA | 5760–5741 | PCR, sequencing | [ | |
| 6 | vanS1 | ATTGTTCAGCATGGAGGGC | 5700–5719 | PCR, sequencing | [ |
| vanH2 | GAGCATGGAATGCATCTGCC | 6060–6041 | PCR | [ | |
| 7 | vanA1 | CATGAATAGAATAAAAGTTGCAATA | 6978–7002 | PCR | [ |
| vanX2 | TTATTTAACGGGGAAATC | 8600–8583 | PCR, sequencing | [ | |
| 8 | vanX-F | ATGGGTATTTTCAGAAGTCCC | 8580–8601 | PCR, sequencing | [ |
| vanZ2 | AATGGGTACGGTAAACGAGC | 10555–10536 | PCR | [ | |
| ORF1-4 | GCATGTAGTGATGAAACACCTAGCTGC | 960–987 | sequencing | [ | |
| vanA2 | CCCCTTTAACGCTAATACCATCAA | 8007–7894 | sequencing | [ | |
| vanY1 | AGAGACGAACCATACCCCAA | 9200–9181 | sequencing | [ | |
| vanY2-R | AGTATGTGTTGATCCGGGAAAC | 9900–9922 | sequencing | this study | |
Clonal relatedness, antimicrobial resistance profiles, and distribution of resistance and virulence determinants among IO and IH outbreak isolates.
| Isolate | MT/PT/ST | MIC VAN (mg/L) | MIC TEI (mg/L) | Resistance phenotypesa,b | Resistance determinantsb,c | Cotransferred resistance | Virulence genes | Pili genesd |
|---|---|---|---|---|---|---|---|---|
| Institute of oncology | ||||||||
| 988 | 1/2-A/17 | >256 | 32 | RIF |
| ERY | — |
|
| 989* | 159/3/78 | >256 | 256 | CHL, GEN, KAN, RIF |
| — |
|
|
| 990 | 1/4-A/18 | >256 | 32 | RIF |
| ERY |
|
|
| 991 | 3/1-A/18 | >256 | 32 | RIF |
| ERY |
|
|
| 992 | 3/1-A/nd | >256 | 32 | RIF |
| ERY |
|
|
| 993 | 3/1-A/nd | >256 | 32 | RIF |
| ERY |
|
|
| 994 | 3/1-A/nd | >256 | 32 | RIF |
| ERY |
|
|
| 995 | 3/1-A/nd | >256 | 24 | RIF, TET |
| ERY |
|
|
| 996 | 3/1-A/nd | >256 | 32 | RIF, TET |
| ERY |
|
|
| 3612 | 3/1-C/nd | >256 | 48 | GEN, RIF, TET |
| ERY |
|
|
| 3613 | 3/1-C/nd | >256 | 32 | RIF, TET |
| ERY |
|
|
| 3614 | 3/1-C/nd | >256 | 32 | RIF, TET |
| ERY |
|
|
| 3615 | 3/1-C/nd | >256 | 32 | RIF, TET |
| ERY |
|
|
| 3616 | 3/1-C/nd | >256 | 32 | RIF, TET |
| ERY |
|
|
| 3617 | 3/1-C/nd | >256 | 32 | RIF, TET |
| ERY |
|
|
| 3618 | 3/1-C/nd | >256 | 32 | RIF, TET |
| ERY |
|
|
| 3620 | 10/5/262 | >256 | 48 | GEN, KAN, RIF, STR, TET |
| ERY |
|
|
| 3621 | 3/1-C/nd | >256 | 32 | RIF, TET |
| ERY |
|
|
| 3622 | 3/1-B/18 | >256 | 32 | RIF, TET |
| ERY |
|
|
| 3623 | 3/1-C/nd | >256 | 48 | RIF, TET |
| ERY |
|
|
| 3624 | 10/5/262 | >256 | 48 | GEN, KAN, RIF, STR, TET |
| no | — |
|
| 3625 | 10/5/nd | >256 | 48 | GEN, KAN, RIF, STR, TET |
| no | — |
|
| 3626 | 10/5/nd | >256 | 48 | GEN, KAN, RIF, STR, TET |
| no | — |
|
| 3627 | 10/5/nd | >256 | 48 | GEN, KAN, RIF, STR, TET |
| ERY | — |
|
| 3628 | 3/1-C/nd | >256 | 64 | RIF, TET |
| ERY |
|
|
| 3629 | 7/2-B/18 | >256 | 48 | GEN, KAN, TET |
| ERY |
|
|
| 3630 | 10/5/nd | >256 | 64 | GEN, KAN, RIF, STR, TET |
| ERY, TET | — |
|
|
|
|
|
|
|
| |||
|
| ||||||||
| Institute of hematology | ||||||||
| 3549 | 11/7-A/202 | >256 | 32 | GEN, KAN, RIF, TET |
| ERY, GEN |
|
|
| 3550x | 7/8/18 | >256 | 48 | GEN, KAN, RIF, STR |
| ERY |
|
|
| 3551 | 159/9/78 | >256 | 32 | GEN, KAN, RIF, STR |
| ERY |
|
|
| 3552* | 7/10/18 | >256 | >256 | KAN, RIF, STR |
| ERY |
|
|
| 3553 | 11/7-A/nd | >256 | 32 | GEN, KAN, RIF, TET |
| ERY |
|
|
| 3554 | 159/6-A/192 | >256 | 48 | GEN, KAN, RIF, STR |
| no |
|
|
| 3555 | 159/6-B/nd | >256 | 48 | GEN, KAN, RIF, STR |
| no |
|
|
| 3556 | 159/6-C/nd | >256 | 32 | GEN, KAN, STR |
| no |
|
|
| 3557x# | 296/11/17 | >256 | 48 | KAN, RIF |
| ERY |
|
|
| 3558 | 159/6-A/nd | >256 | 48 | GEN, KAN, PEN |
| no |
|
|
| 3559 | 159/6-D/nd | >256 | 48 | GEN, KAN, PEN |
| no |
|
|
| 3560 | 1/7-B/18 | >256 | 48 | GEN, KAN, RIF, TET |
| ERY |
|
|
| 3561 | 11/4-C/202 | >256 | 32 | GEN, KAN, RIF, TET |
| ERY |
|
|
| 3562# | 1/4-B/18 | >256 | 32 | GEN, KAN, RIF, TET |
| no |
|
|
| 3563 | 159/6-E/192 | >256 | 48 | GEN, KAN, RIF |
| no |
|
|
| 3564y | 7/12/18 | >256 | 48 | GEN, KAN, RIF, TET |
| ERY |
|
|
| 3567y# | 144/13/18 | >256 | 48 | GEN, KAN, RIF, TET |
| ERY |
|
|
|
|
|
|
|
|
| |||
|
| ||||||||
|
|
|
|
|
|
| |||
nd: not determined; no: no transconjugants obtained; two isolates with the prototype Tn1546 marked with an asterisk; #isolates from blood; aall isolates resistant to vancomycin, teicoplanin, penicillin, ampicillin, ciprofloxacin, erythromycin, and clindamycin; bfive isolates with tet(M) showed intermediate susceptibility to tetracycline and one isolate with tet(M) was susceptible to this compound, one tetracycline-resistant isolate (3567) was negative for the determinants tested; for four isolates with aad6 the MIC values for streptomycin increased (512 mg/L); one isolate with cat showed an intermediate resistance to chloramphenicol; call isolates were positive for the vanA gene; dall isolates positive for the pilA gene; x,yisolates from the same patients “X” and “Y”; RIF: rifampin; CHL: choramphenicol; GEN: gentamicin (HLGR); STR: streptomycin (HLSR); KAN: kanamycin (HLKR); TET: tetracycline. For the summarized results, the number of isolates is given in brackets.
Figure 1Distribution (% of isolates) of plasmid-specific genes, selected virulence genes, and resistance determinants among isolates from outbreak at the Institute of Oncology and Institute of Hematology, Warsaw.
Figure 2PFGE-based dendrogram of selected isolates from outbreaks in IO and IH, representing all PTs. Normalization performed by the use of reference Lambda Ladder PFG Marker (New England BioLabs, UK). The phylogenetic tree was constructed by the use of Dice coefficient (optimization, 0.5%; band tolerance, 1.3%) and UPGMA clustering.
Figure 3PFGE of S1-digested total DNA of selected 27 VREfm isolates, visualized by ethidium bromide staining (a) and subjected to Southern hybridization with the following probes: vanA (b), rep17pRUM (c), axe-txe (d), rep pLG1 (e), pilA (f), aac(6′)-Ie-aph(2′′)-Ia (g), rep18pEF418 (h), rep2pRE25 (i), and ω - (j). Lanes A–a, isolates designation as described in Table 3.
Plasmid profiles and colocalization of particular genes on vanA and other plasmids among selected 27 VREfm isolates.
| Letter code | Isolate | MT/PT/ST |
| Other plasmids in kb (hybridizing probes) |
|---|---|---|---|---|
| IO ( | ||||
| A | 988# | 1/2-A/17 | 100 ( | <30, 150 ( |
| B | 989∗# | 159/3/78 | <30, 200 | 110 ( |
| C | 990# | 1/4-A/18 | 100 ( | 175, 230 ( |
| D | 991# | 3/1-A/18 | 100 (rep17, pilA) | 65 ( |
| E | 3612# | 3/1-C/nd | 100 ( | 70 ( |
| F | 3620# | 10/5/262 | 100 ( | 65, 150 ( |
| G | 3622# | 3/1-B/18 | 100 ( | 70 ( |
| H | 3623# | 3/1-C/nd | 100 ( | 70 ( |
| I | 3624 | 10/5/262 | 100 ( | 40, 65 ( |
| J | 3628# | 3/1-C/nd | 100 ( | 70 ( |
| K | 3629# | 7/2-B/18 | 100 ( | 235 ( |
|
| ||||
| IH ( | ||||
| L | 3549# | 11/7-A/202 | 100 ( | 70 ( |
| M | 3550x# | 7/8/18 | 45 ( | 60 ( |
| N | 3551# | 159/9/78 | 45 ( | 40 ( |
| O | 3552∗# | 7/10/18 | <30, 170 | 65 ( |
| P | 3554 | 159/6-A/192 | 50 ( | 40 ( |
| Q | 3555 | 159/6-B/nd | 50 ( | 40 ( |
| R | 3556 | 159/6-C/nd | 50 ( | 40 ( |
| S | 3557x# | 296/11/17 | 100 ( | 40 ( |
| T | 3558 | 159/6-A/nd | 50 ( | 40 ( |
| U | 3559 | 159/6-D/nd | 50 ( | 40 ( |
| V | 3560# | 1/7-B/18 | 100 ( | 85 ( |
| W | 3561# | 11/4-C/202 | 100 ( | 240 ( |
| X | 3562 | 1/4-B/18 | 100 ( | 240 ( |
| Y | 3563 | 159/6-E/192 | 50 ( | 40 ( |
| Z | 3564y# | 7/12/18 | 70 ( | 60 ( |
| a | 3567y# | 144/13/18 | 315 ( | 75 ( |
Letter code of each isolate corresponds to the designation used in Figure 2; nd: not determined; two isolates with the prototype Tn1546 marked with an asterisk; x,yisolates from the same patients “X” and “Y”; #isolates positive in conjugation.